Technical Analysis for OTIC - Otonomy, Inc.
|Grade||Last Price||% Change||Price Change|
OTIC closed up 0.5 percent on Wednesday, January 16, 2019, on 17 percent of normal volume. The price action carved out a bearish shooting star candlestick pattern. That may indicate a downside reversal. Look for price to trade beneath the low of the shooting star for confirmation. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.
|Weak or Absent||Down||Down||Up|
|See historical OTIC trend table...|
|Date||Alert Name||Type||% Chg|
|Jan 16||Shooting Star Candlestick||Bearish||0.00%|
|Jan 16||Lizard Bearish||Bearish Day Trade Setup||0.00%|
|Jan 16||Non-ADX 1,2,3,4 Bearish||Bearish Swing Setup||0.00%|
|Jan 16||Weak + Overbought||Other||0.00%|
|Jan 16||Wide Bands||Range Expansion||0.00%|
|Jan 16||Weak, Overbought and Reversal Signs||Reversal||0.00%|
|Jan 16||Overbought Stochastic||Strength||0.00%|
|Jan 16||Up 3 Days in a Row||Strength||0.00%|
|Jan 15||Non-ADX 1,2,3,4 Bearish||Bearish Swing Setup||0.50%|
|Jan 15||Spinning Top||Other||0.50%|
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicatorsBasic chart:
Otonomy, Inc. develops and commercializes therapeutics for the treatment of ear diseases and disorders primarily in the United States. Its lead product candidate is AuriPro, a sustained-exposure antibiotic, which is in Phase III clinical trials to treat pediatric patients with middle ear effusion at the time of tympanostomy tube placement surgery. The company also develops OTO-104, a sustained-exposure formulation of the steroid dexamethasone that is in a Phase IIb clinical trial for the treatment of patients with Ménière's disease; and OTO-311, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in preclinical development as a potential treatment for tinnitus. Otonomy, Inc. was founded in 2008 and is headquartered in San Diego, California.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more OTIC news...
|52 Week High||6.45|
|52 Week Low||1.5|
|200-Day Moving Average||3.1734|
|50-Day Moving Average||2.1802|
|20-Day Moving Average||1.88|
|10-Day Moving Average||1.964|
|Average True Range||0.1486|
|Chandelier Exit (Long, 3 ATRs )||1.9242|
|Chandelier Exit (Short, 3 ATRs )||1.9458|
|Upper Bollinger Band||2.1864|
|Lower Bollinger Band||1.5736|
|Percent B (%b)||0.74|
|MACD Signal Line||-0.0865|
|Market Cap||61.51 Million|
|Num Shares||30.3 Million|
|Price-to-Earnings (P/E) Ratio||-0.59|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||2.19|
|Resistance 3 (R3)||2.20||2.16||2.16|
|Resistance 2 (R2)||2.16||2.12||2.16||2.15|
|Resistance 1 (R1)||2.10||2.10||2.13||2.08||2.14|
|Support 1 (S1)||1.99||2.01||2.02||1.98||1.92|
|Support 2 (S2)||1.95||1.99||1.94||1.91|
|Support 3 (S3)||1.88||1.95||1.90|
|Support 4 (S4)||1.87|